Severe dysglycemia with the fluoroquinolones: A class effect?

Clinical Infectious Diseases

Volumn 49, Issue 3, 2009, Pages 402-408

  Aspinall, Sherrie L ^a,b,c   Good, Chester B ^a,b,c   Jiang, Rong ^a   McCarren, Madeline ^a   Dong, Diane ^a   Cunningham, Francesca E ^a,d  

^a Veterans Affairs Center for Medication Safety   (United States)

^b Veterans Affairs Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR;

AGED; ANTI-BACTERIAL AGENTS; BLOOD GLUCOSE; COHORT STUDIES; FEMALE; FLUOROQUINOLONES; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 67651115472     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/600294     Document Type: Article

References (35)

1. Fish DN, North DS. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy 2001; 21:35-59.
2. Keam SJ, Croom KF, Keating GM. Gatifloxacin: a review of its use in the treatment of bacterial infections in the U.S. Drugs 2005; 65:695-724.
3. Tequin package insert. Princeton, NJ: Bristol-Myers Squibb, 2006.
4. Baker SE, Hangii MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother 2002; 36:1722-6.
5. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002; 113:232-4.
6. Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 2003; 16:455-7.
7. Donaldson AR, Vandiver JR, Finch CK. Possible gatifloxacin-induced hyperglycemia. Ann Pharmacother 2004; 38:602-5.
8. LeBlanc M, Belanger C, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacotherapy 2004; 24:926-31.
9. Arce FC, Bhasin RS, Pasmantier R. Severe hyperglycemia during ga- tifloxacin therapy in patients without diabetes. Endocr Pract 2004; 10:40-4.
10. Bhatia V, Bhatia R, Dhindsa S. Gatifloxacin-induced hyperglycemia. Endocr Pract 2004; 10:86.
11. Stading JA, Chock AWY, Skrabal MZ, Faulkner MA. Development of diabetes after gatifloxacin therapy. Am J Health Syst Pharm 2005; 62:2293-5.
12. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005; 25:1296-302.
13. Orlander JD, Serrao R. Gatifloxacin-induced hyperglycemia. Infect Dis Clin Prac 2004; 12:230-2.
14. Beste LA, Mersfelder TL. Hyperglycemia and gatifloxacin: a case report and summary of current literature. Am J Geriatr Pharmacother 2005;3:262-5.
15. Coblio NA, Mowrey K, McCright P, Means H, McCormick MT. Use
16. of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am J Health Syst Pharm 2004; 61:2545-8.
17. Park-Wylie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352-61.
18. Bhasin RS, Arce FC, Pasmantier R. Hypoglycemia associated with the use of gatifloxacin. Am J Med Sci 2005; 330:250-3.
19. Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC. Gatifloxacin-induced hyperglycemia. Ann Intern Med 2004; 141:968-9.
20. Khovidhunkit W, Sunthornyothin S. Hypoglycemia, hyperglycemia, and gatifloxacin. Ann Intern Med 2004; 141:969.
21. Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005; 25:1303-9.
22. Lodise T, Graves J, Miller C, Mohr JF, Lomaestro B, Smith RP. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients. Pharmacotherapy 2007; 27:1498-505.
23. Wang S, Rizvi AA. Levofloxacin-induced hypoglycemia in a nondiabetic patient. Am J Med Sci 2006; 331:334-5.
24. Roberge RJ, Kaplan R, Frank R, Fore C. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000; 36:160-3.
25. Whiteley M, Worlding J, Patel S, Gibbs KB. Hypoglycaemia in a diabetic patient, associated with ciprofloxacin therapy. Pract Diabetes 1993; 10:35.
26. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004; 24:1807-12.
27. Gibert AE, Porta FS. Hypoglycemia and levofloxacin: a case report. Clin Infect Dis 2008; 46:1126-7.
28. Hartnell NR, Wilson JP. Replication of the Weber effect using post- marketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004; 24:743-9.
29. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49:1373-9.
30. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 1998:255-6.
31. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996; 117:372-6.
32. Saraya A, Yokokura M, Gonoi T, Seino S. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004; 497:111-7.
33. Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003; 52:435-40.
34. Owens RC Jr. Fluoroquinolone-associated dysglycemias: a tale of two toxicities. Pharmacotherapy 2005; 25:1291-5.
35. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41:S144-57.